[1]周浩 兰富霞 徐英.经导管主动脉瓣植入术后发生脑血管事件的研究进展[J].心血管病学进展,2023,(11):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]
　ZHOU Hao,LAN Fuxia,XU Ying.Cerebrovascular Events After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2023,(11):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]
点击复制

经导管主动脉瓣植入术后发生脑血管事件的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年11期
页码:
965
栏目:
综述
出版日期:
2023-11-25

文章信息/Info

Title:
Cerebrovascular Events After Transcatheter Aortic Valve Implantation
作者:
周浩 兰富霞 徐英
(四川大学华西医院心脏内科/四川大学华西护理学院,四川 成都 610041)
Author(s):
ZHOU Hao; LAN Fuxia; XU Ying
(Department of Cardiology,West China Hospital,Sichuan University/West China Hospital School of Nursing,Sichuan University,Chengdu 610041,Sichuan,China)
关键词:
经导管主动脉瓣植入术; 脑血管事件; 抗血栓治疗; 脑血栓保护装置
Keywords:
Transcatheter aortic valve implantation; Cerebrovascular events; Antithrombotic therapy; Cerebral embolic protection devices
DOI:
10.16806/j.cnki.issn.1004-3934.2023.11.002
摘要:
主动脉瓣狭窄是中老年人最常见的瓣膜疾病，经导管主动脉瓣植入术已成为治疗有症状的重度主动脉瓣狭窄患者的一种微创术式，极大地提高了主动脉瓣狭窄患者的生存率和生活质量。然而，脑血管事件是经导管主动脉瓣植入术的严重并发症之一，严重影响患者预后。现对经导管主动脉瓣植入术后并发脑血管事件的机制和预防策略等进行综述，为提高经导管主动脉瓣植入术后发生脑血管事件的管理质量提供参考。
Abstract:
Aortic stenosis(AS) is the most common valvular disease in the middle-aged and elderly. Transcatheter aortic valve implantation(TAVI) has become a minimally invasive procedure for the treatment of severe symptomatic AS patients,which greatly improves the survival rate and quality of life of AS patients. However,cerebrovascular events(CVE) remain one of the serious complications of TAVI,which seriously affects the prognosis of patients. This article reviews the mechanism and prevention strategies of postoperative CVE,so as to provide reference for improving the management quality of CVE after TAVI

参考文献/References:

[1].Strange G,Stewart S,Playford D,et al. Risk for mortality with increasingly severe aortic stenosis:an international cohort study[J]. J Am Soc Echocardiogr,2023,36(1):60-68.e2.
[2].Lee C H,Inohara T,Hayashida K,et al. Transcatheter aortic valve replacement in Asia:present status and future perspectives[J]. JACC Asia,2021,1(3):279-293.
[3].白琳,彭勇,赵振刚,等. 2022版《经导管主动脉瓣植入术后抗血栓治疗中国专家共识》解读[J]. 华西医学,2022,37(4):1-6.
[4].中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志,2020,28(6):301-309.
[5].Takagi K,Naganuma T,Tada N,et al. The predictors of peri-procedural and sub-acute cerebrovascular events following TAVR from OCEAN-TAVI registry[J]. Cardiovasc Revasc Med,2020,21(6):732-738.
[6].Suhai FI,Varga A,Szilveszter B,et al. Predictors and neurological consequences of periprocedural cerebrovascular events following transcatheter aortic valve implantation with self-expanding valves[J]. Front Cardiovasc Med,2022,9:951943.
[7].VARC-3 Writing Committee,Généreux P,Piazza N,et al. Valve Academic Research Consortium 3:updated endpoint definitions for aortic valve clinical research[J]. Eur Heart J,2021,42(19):1825-1857.
[8].Van Nieuwkerk A,Romaguera R,Tchetche D,et al. Stroke after transcatheter aortic valve implantation:incidence and temporal trends between 2007 and 2022[J]. J Am Coll Cardiol,2023,81(8 suppl):823-823.
[9].Almarzooq ZI,Kazi DS,Wang Y,et al. Outcomes of stroke events during transcatheter aortic valve implantation[J]. EuroIntervention,2022,18(4):e335-e344.
[10].Ricco JB,Castagnet H,Christiaens L,et al. Predictors of early stroke or death in patients undergoing transcatheter aortic valve implantation[J]. J Stroke Cerebrovasc Dis,2021,30(8):105912.
[11].Linder M,Higgen FL,Voigtl?nder L,et al. Stroke events after transcatheter aortic valve implantation:temporal relationships and affected brain regions[J]. Am Heart J,2022,247:112-122.
[12].Ciobanu AO,Gherasim L,Vinereanu D. Risk of stroke after transcatheter aortic valve implantation:epidemiology,mechanism,and management[J]. Am J Ther,2021,28(5):e560-e572.
[13].Richter I,Abdel-Wahab M,Desch S,et al. Cerebral embolic protection in patients undergoing transcatheter aortic valve implantation:recent advances[J]. Kardiol Pol,2022,80(6):644-650.
[14].Nijenhuis VJ,Ten Berg JM,Hengstenberg C,et al. Usefulness of clopidogrel loading in patients who underwent transcatheter aortic valve implantation(from the BRAVO-3 randomized trial)[J]. Am J Cardiol,2019,123(9):1494-1500.
[15].Nombela-Franco L,Webb JG,de Jaegere PP,et al. Timing, predictive factors,and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation[J]. Circulation,2012,126(25):3041-3053.
[16].Knol WG,Budde RPJ,Mahtab EAF,et al. Intimal aortic atherosclerosis in cardiac surgery:surgical strategies to prevent embolic stroke[J]. Eur J Cardiothorac Surg,2021,60(6):1259-1267.
[17].Kawakami R,Gada H,Rinaldi MJ,et al. Characterization of cerebral embolic capture using the SENTINEL device during transcatheter aortic valve implantation in low to intermediate-risk patients:the SENTINEL-LIR study[J]. Circ Cardiovasc Interv,2022,15(4):e011358.
[18].Andreasen C,Gislason GH,K?ber L,et al. Incidence of ischemic stroke in individuals with and without aortic valve stenosis:a Danish retrospective cohort study[J]. Stroke,2020,51(5):1364-1371.
[19].Cristiano L,Coppolino F,Donatiello V,et al. Use of dexmedetomidine in transfemoral transcatheter aortic valve implantation(tf-TAVI) procedures[J]. Adv Ther,2020,37:2337-2343.
[20].Biccirè FG,Tanzilli G,Prati F,et al. Prediction of new onset atrial fibrillation in patients with acute coronary syndrome undergoing percutaneous coronary intervention using the C2HEST and mC2HEST scores:a report from the multicenter REALE-ACS registry[J]. Int J Cardiol,2023,386:45-49.
[21].Ryan T,Grindal A,Jinah R,et al. New-onset atrial fibrillation after transcatheter aortic valve replacement:a systematic review and meta-analysis[J]. JACC Cardiovasc Interv,2022,15(6):603-613.
[22].Doshi R,Pisipati S,Taha M,et al. Incidence,30-day readmission rates and predictors of readmission after new onset atrial fibrillation who underwent transcatheter aortic valve replacement[J]. Heart Lung,2020,49(2):186-192.
[23].Fukamizu S,Hojo R,Kitamura T,et al. Recurrent ischemic stroke in patients with atrial fibrillation ablation and prior stroke:a study based on etiological classification[J]. J Arrhythm,2020,36(1):95-104.
[24].Miyasaka M,Sharma RP,Maeno Y,et al. Investigation of computed-tomography based predictors of acute stroke related to transcatheter aortic valve replacement:aortic wall plaque thickness might be a predictive parameter of stroke[J]. J Invasive Cardiol,2020,32(2):E18-E26.
[25].Armijo G,Nombela-Franco L,Tirado-Conte G. Cerebrovascular events after transcatheter aortic valve implantation[J]. Front Cardiovasc Med,2018,5:104.
[26].Writing Committee Members,Otto CM,Nishimura RA,et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2021,77(4):e25-e197.
[27].Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease:developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J,2022,43(7):561-632.
[28].Bernelli C,Chieffo A,Montorfano M,et al. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation[J]. JACC Cardiovasc Interv,2014,7(2):140-151.
[29].Zilberszac R,Chandiramani R,Hengstenberg C,et al. Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease:results from the BRAVO-3 randomized trial[J]. Catheter Cardiovasc Interv,2020,96(3):E377-E386.
[30].Ichibori Y,Mizote I,Maeda K,et al. Clinical outcomes and bioprosthetic valve function after transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone[J]. Circ J,2017,81(3):397-404.
[31].Rodés-Cabau J,Masson JB,Welsh RC,et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve:the ARTE(Aspirin Versus Aspirin+ Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial[J]. JACC Cardiovasc Interv,2017,10(13):1357-1365.
[32].Butala NM,Makkar R,Secemsky EA,et al. Cerebral embolic protection and outcomes of transcatheter aortic valve replacement:results from the transcatheter valve therapy registry[J]. Circulation,2021,143(23):2229-2240.
[33].Kapadia SR,Kodali S,Makkar R,et al. Protection against cerebral embolism during transcatheter aortic valve replacement[J]. J Am Coll Cardiol,2017,69(4):367-377.
[34].Haussig S,Mangner N,Dwyer MG,et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis:the CLEAN-TAVI randomized clinical trial[J]. JAMA,2016,316(6):592-601.
[35].van Mieghem NM,van Gils L,Ahmad H,et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation:the randomised MISTRAL-C trial[J]. EuroIntervention,2016,12(4):499-507.
[36].Kapadia SR,Makkar R,Leon M,et al. Cerebral embolic protection during transcatheter aortic-valve replacement[J]. N Engl J Med,2022,387(14):1253-1263.
[37].Lansky AJ,Schofer J,Tchetche D,et al. A prospective randomized evaluation of the TriGuard? HDH embolic DEFLECTion device during transcatheter aortic valve implantation:results from the DEFLECT Ⅲ trial[J]. Eur Heart J,2015,36(31):2070-2078.
[38].Nazif TM,Moses J,Sharma R,et al. Randomized evaluation of TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement:REFLECT Ⅱ[J]. JACC Cardiovasc Interv,2021,14(5):515-527.

相似文献/References:

[1]王慧,饶莉.经导管主动脉瓣植入术的影像学研究进展[J].心血管病学进展,2015,(5):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
　WANG Hui,RAO Li.Advances in Study of Imaging of Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(11):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
[2]蒲华霞 彭礼清.多层螺旋CT在经导管主动脉瓣植入术前评估中的研究进展[J].心血管病学进展,2019,(9):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
　PU HuaxiaPeng Liqing.Preoperative Evaluation of Transcatheter Aortic Valve Implantation with Multi-detector Computed Tomography[J].Advances in Cardiovascular Diseases,2019,(11):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
[3]张文博 谢进生.经导管主动脉瓣中瓣植入术的并发症及其处理进展[J].心血管病学进展,2021,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
　ZHANG Wenbo,XIE Jinsheng.Complications and Management of Valve-in-valve Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(11):1.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[4]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
　DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(11):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[5]何佳玲 陈应忠 刘浩然 叶滔 谢轲 徐俊波 刘汉雄 蔡琳.预防性静脉-动脉体外膜肺氧合支持下的经导管主动脉瓣植入术[J].心血管病学进展,2022,(2):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
　HE JialingCHEN YingzhongLIU HaoranYE TaoXIE KeXU Junbo,LIU HanxiongCAI Lin.Prophylactic Venous-Arterial Extracorporeal Membrane Oxygenation Supported Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(11):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
[6]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
　WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(11):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]

更新日期/Last Update: 2023-12-13